In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates
Open Access
- 26 November 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (2) , 277-284
Abstract
Purpose: Overproduction of the intrinsic chromosomally-encoded AmpC β-lactamase is one of the main mechanisms responsible for broad-spectrum β-lactam resistance in Pseudomonas aeruginosa. Our study aimed to evaluate the in-vitro activity of anti-pseudomonal β-lactam molecules associated with the recently-developed and commercially-available β-lactamase inhibitors, namely avibactam, relebactam and vaborbactam, against P. aeruginosa isolates overproducing their AmpC. Methods: MIC values of ceftazidime, cefepime, meropenem, imipenem and ceftolozane with or without β-lactam inhibitor were determined for 50 AmpC-overproducing P. aeruginosa clinical isolates. MIC breakpoints for resistance were retained at 8 mg/L for β-lactams and β-lactam/β-lactamase inhibitor combinations containing ceftazidime, cefepime and meropenem, while 4 mg/L was used for those containing imipenem and ceftolozane. The concentration of all β-lactamases inhibitors was fixed at 4 mg/L, except for vaborbactam (8 mg/L). Results: The rates of isolates not being resistant to ceftazidime, cefepime, meropenem, imipenem and ceftolozane were found at 12%, 22%, 34%, 8% and 74%, respectively. When combined with avibactam, those rates increased to 60%, 62%, 60%, 46%, and 80%, respectively. The highest rates were found with relebactam-based combinations, being 76%, 64%, 66%, 76% and 84%, respectively. By contrast, associations with vaborbactam did not lead to significantly increased “non-resistance” rates. Conclusion: Our results showed that all combinations including relebactam led to higher “non-resistance” rates against AmpC-overproducing P. aeruginosa clinical isolates. The best activity was achieved by combining ceftolozane and relebactam, that might therefore be considered as an excellent clinical alternative against AmpC overproducers.Keywords
Funding Information
- University of Fribourg
This publication has 41 references indexed in Scilit:
- Rapid Detection of Carbapenemase-Producing Pseudomonas sppJournal of Clinical Microbiology, 2012
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitorsCurrent Opinion in Microbiology, 2011
- Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter StudyAntimicrobial Agents and Chemotherapy, 2011
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins ofPseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2010
- Updated Functional Classification of β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- Antibacterial-ResistantPseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance MechanismsClinical Microbiology Reviews, 2009
- Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2009
- Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosaClinical Microbiology and Infection, 2007
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2000